{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-158719","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.471547+00:00","generated_at":"2026-05-18T06:39:53.905634+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atara resubmits tab-cel BLA to FDA for EBV+ PTLD; cash ~$22M, runway into Q1 2026","bullets":["Atara resubmitted BLA to FDA for tabelecleucel (tab-cel) for EBV+ PTLD after CRL related to manufacturing observations.","Pivotal ALLELE study showed 48.8% ORR (p<0.0001); no FDA-approved therapies in this setting.","Cash, cash equivalents and short-term investments ~$22M as of June 30, 2025; cost cuts extend runway into Q1 2026.","$40M milestone payment from Pierre Fabre due upon FDA approval; plus double-digit tiered royalties on net sales.","Transitioning tab-cel clinical studies to Pierre Fabre; Atara maintains BLA sponsorship."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-158719","json":"https://secwatch.observer/filing/0001193125-25-158719.json","markdown":"https://secwatch.observer/filing/0001193125-25-158719.md","text":"https://secwatch.observer/filing/0001193125-25-158719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/0001193125-25-158719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:39:53.905634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}